Home › Trials › NCT07150845

EVO756 for adults with moderate to severe atopic dermatitis

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis

Phase 2 Interventional Evommune, Inc. · NCT07150845

This trial will test different doses of EVO756 versus placebo to see if it reduces rash and itch in adults with moderate to severe atopic dermatitis.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment120 (estimated)
Ages18 Years and up
SexAll
SponsorEvommune, Inc. Industry-sponsored
Locations29 sites (Phoenix, Arizona and 28 other locations)
Trial IDNCT07150845 on ClinicalTrials.gov

What this trial studies

This is a Phase 2b, randomized interventional trial comparing multiple doses of EVO756 to placebo in adults with chronic moderate-to-severe atopic dermatitis. Eligible participants must have had AD for at least 6 months and meet objective severity thresholds (IGA ≥3, EASI ≥16, BSA ≥10%). The study will monitor skin signs, patient-reported itch, and safety laboratory and clinical measures over the treatment period. Outcomes will determine which dose, if any, provides clinically meaningful skin improvement with an acceptable safety profile.

Who should consider this trial

Good fit: Adults with chronic atopic dermatitis of at least 6 months' duration who have moderate-to-severe disease (IGA ≥3, EASI ≥16, BSA ≥10%) and who meet screening safety requirements are the intended participants.

Not a fit: Patients with mild disease, significant laboratory or clinical abnormalities, recent major AD flare, interfering skin comorbidities, or who require disallowed medications are unlikely to be eligible or to benefit from this trial.

Why it matters

Potential benefit: If successful, EVO756 could become an additional treatment option that reduces rash and itch for adults with moderate to severe atopic dermatitis.

How similar studies have performed: Other targeted therapies for moderate-to-severe atopic dermatitis (for example some biologics and JAK inhibitors) have shown benefit, but EVO756 is a novel agent being tested here in a Phase 2b setting.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Chronic AD that has been present for ≥6 months
* Validated-Investigator's Global Assessment score of ≥3
* EASI of ≥16
* BSA of AD involvement of ≥10%

Exclusion Criteria:

* Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening
* Use of certain medications
* Presence of skin comorbidities or other condition(s) that may interfere with study assessments
* Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry

Where this trial is running

Phoenix, Arizona and 28 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Atoptic Dermatitisatopic dermatitiseczemaitch
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.